This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Diabetes
  • /
  • Canagliflozin reduces epicardial fat in patients w...

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus.

Read time: 1 mins
Published:3rd Oct 2017
Author: Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D et al.
Availability: Free full text
Ref.:Diabetol Metab Syndr. 2017;9:78.

Background: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease.

Methods and results: We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes.

Conclusion: Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).


Read abstract on library site

Access full article